Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GMP Finalization Should Be Top CFSAN Priority, CHPA Urges

This article was originally published in The Tan Sheet

Executive Summary

The Consumer Healthcare Products Association is urging FDA to "commit to finalization" of dietary supplement GMPs as part of the Center for Food Safety & Applied Nutrition's fiscal 2005 priorities

You may also be interested in...



CFSAN’s Brackett Says Supplement GMPs Remain Top Priority

FDA is now aiming to get a final rule out on dietary supplement good manufacturing practices by the end of 2004

FDA Issues Call For Data On Unreviewed OTCs To Complete Drug Review

FDA is requesting information on whether urinary analgesic/antiseptic products are appropriate for self-medication in a call for data on a range of products eligible for the OTC drug review. The notice was published in the Federal Register Dec. 31

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS097168

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel